LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Начало・Списък с акции・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

3.92 0.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.8

Максимум

3.99

Ключови измерители
By Trading Economics
Приходи	-21M 41M
Продажби	59M 107M
P/E Средно за сектора	6.323 50.102
EPS	0.24
Марж на печалбата	38.282
Служители	100
EBITDA	64M 73M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+27.55% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-110M 645M
Предишно отваряне	3.66
Предишно затваряне	3.92

Настроения в новините

By Acuity

93%

3 / 344 Класиране в Healthcare

Ironwood Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.05.2026 г., 16:52 ч. UTC

Значими събития в новините

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26.05.2026 г., 23:57 ч. UTC

Печалби

Sociedad Quimica 1Q Rev $1.76B >SQM

26.05.2026 г., 23:57 ч. UTC

Печалби

Sociedad Quimica 1Q EPS $1.28 >SQM

26.05.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26.05.2026 г., 21:54 ч. UTC

Печалби

Webco Industries 3Q EPS $11.61 >WEBC

26.05.2026 г., 21:54 ч. UTC

Печалби

Webco Industries 3Q Sales $179.6M >WEBC

26.05.2026 г., 21:48 ч. UTC

Пазарно говорене

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26.05.2026 г., 21:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

26.05.2026 г., 20:58 ч. UTC

Придобивния, сливания и поглъщания

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

26.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

26.05.2026 г., 19:22 ч. UTC

Пазарно говорене

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26.05.2026 г., 19:17 ч. UTC

Пазарно говорене

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26.05.2026 г., 18:56 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26.05.2026 г., 18:03 ч. UTC

Пазарно говорене

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26.05.2026 г., 17:42 ч. UTC

Пазарно говорене

Grains Await Fresh Trading Catalyst -- Market Talk

26.05.2026 г., 17:33 ч. UTC

Пазарно говорене

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26.05.2026 г., 17:21 ч. UTC

Пазарно говорене

Canada Faces a Labor Market Squeeze -- Market Talk

26.05.2026 г., 16:52 ч. UTC

Пазарно говорене

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26.05.2026 г., 16:43 ч. UTC

Пазарно говорене

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26.05.2026 г., 16:24 ч. UTC

Пазарно говорене

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26.05.2026 г., 16:21 ч. UTC

Пазарно говорене

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Auto & Transport Roundup: Market Talk

26.05.2026 г., 16:16 ч. UTC

Пазарно говорене

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26.05.2026 г., 16:01 ч. UTC

Пазарно говорене

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26.05.2026 г., 15:21 ч. UTC

Пазарно говорене

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ironwood Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

27.55% нагоре

12-месечна прогноза

Среден 5 USD 27.55%

Висок 5 USD

Нисък 5 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Ironwood Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Ironwood Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

3 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.